Please use this identifier to cite or link to this item:
Title: Tolerogenic insulin peptide therapy precipitates type 1 diabetes
Author: Bergman, Marie-Louise
Lopes-Carvalho, Thiago
Martins, Ana-Catarina
Grieco, Fabio A.
Eizirik, Décio L.
Demengeot, Jocelyne
Keywords: Autoimmunity
Issue Date: 23-May-2017
Publisher: Rockefeller University Press
Citation: Tolerogenic insulin peptide therapy precipitates type 1 diabetes Marie-Louise Bergman, Thiago Lopes-Carvalho, Ana-Catarina Martins, Fabio A. Grieco, Décio L. Eizirik, Jocelyne Demengeot Journal of Experimental Medicine Jul 2017, 214 (7) 2153-2156; DOI: 10.1084/jem.20160471
Abstract: Daniel et al. ( have previously published in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Our study now challenges these results and shows that osmotic pump delivery of the modified insulin peptide R22E did not prevent hyperglycemia, accelerated disease onset, increased its incidence, and worsened insulitis.
Description: This deposit is composed by the main article plus the supplementary materials of the publication.
Peer review: yes
DOI: 10.1084/jem.20160471
Publisher Version:
Appears in Collections:LP - Letters

Files in This Item:
File Description SizeFormat 
Demengeot_J.Exp.Med.(2017).pdfmain article986,24 kBAdobe PDFView/Open
Demengeot_J.Exp.Med.(2017)_SM.pdfsupplementary materials638,25 kBAdobe PDFView/Open

FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.